Literature DB >> 25382770

Clot waveform analysis in patients with haemophilia A.

T Siegemund1, U Scholz, R Schobess, A Siegemund.   

Abstract

UNLABELLED: Clot waveform analysis extends the interpretation of aPTT measurement curves. The curve is mathematically processed to obtain information about fibrin formation kinetics including semiquantitative determination of thrombin, prothrombinase and tenase activity. PATIENTS,
METHOD: In this study the feasibility of clot waveform analysis for monitoring of haemophilia A was investigated using blood samples from healthy controls as well as haemophilia A patients under various clinical conditions.
RESULTS: Thrombin, prothrombinase and tenase activity show a high correlation to factor VIII levels. Tenase activity was found to exhibit a linear relationship to factor VIII levels over a very large concentration range and was able to discriminate patients with severe, moderate and mild haemophilia.
CONCLUSION: Clot waveform analysis is an easy, fast and cheap method to access disturbances in clot formation and can be done without any additional measurements beside an aPTT.

Entities:  

Keywords:  Activated partial thromboplastin time; fibrin formation kinetics; haemophilia; prothrombinase; tenase; thrombin

Mesh:

Substances:

Year:  2014        PMID: 25382770     DOI: 10.5482/HAMO-14-02-0016

Source DB:  PubMed          Journal:  Hamostaseologie        ISSN: 0720-9355            Impact factor:   1.778


  7 in total

1.  An Evaluation of the Activated Partial Thromboplastin Time Waveform.

Authors:  Takeshi Matsumoto; Hideo Wada; Naoki Fujimoto; Junki Toyoda; Yasunori Abe; Kohshi Ohishi; Yoshiki Yamashita; Makoto Ikejiri; Kei Hasegawa; Kei Suzuki; Hiroshi Imai; Kaname Nakatani; Naoyuki Katayama
Journal:  Clin Appl Thromb Hemost       Date:  2017-09-08       Impact factor: 2.389

2.  Elevated activated partial thromboplastin time-based clot waveform analysis markers have strong positive association with acute venous thromboembolism.

Authors:  Chuen Wen Tan; McVin Hua Heng Cheen; Wan Hui Wong; Ian Qianhuang Wu; Brian Lee Wei Chua; Sahul Hameed Ahamedulla; Lai Heng Lee; Heng Joo Ng
Journal:  Biochem Med (Zagreb)       Date:  2019-06-15       Impact factor: 2.313

3.  Diagnostic analysis of lupus anticoagulant using clot waveform analysis in activated partial thromboplastin time prolonged cases: A retrospective analysis.

Authors:  Kazunori Kanouchi; Hiroto Narimatsu; Toru Shirata; Keita Morikane
Journal:  Health Sci Rep       Date:  2021-03-12

4.  Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors.

Authors:  Cho Yeow Koh; Norrapat Shih; Christina Y C Yip; Aaron Wei Liang Li; Weiming Chen; Fathiah S Amran; Esther Jia En Leong; Janaki Krishnamoorthy Iyer; Grace Croft; Muhammad Ibrahim Bin Mazlan; Yen-Lin Chee; Eng-Soo Yap; Dougald M Monroe; Maureane Hoffman; Richard C Becker; Dominique P V de Kleijn; Vaishali Verma; Amita Gupta; Vijay K Chaudhary; A Mark Richards; R Manjunatha Kini; Mark Y Chan
Journal:  Nat Commun       Date:  2021-11-25       Impact factor: 14.919

5.  Usefulness of the second-derivative curve of activated partial thromboplastin time on the ACL-TOP coagulation analyzer for detecting factor deficiencies.

Authors:  Naoki Tokunaga; Chihiro Inoue; Toshiyuki Sakata; Kumiko Kagawa; Masahiro Abe; Norimichi Takamatsu; Takayuki Nakao; Toshio Doi
Journal:  Blood Coagul Fibrinolysis       Date:  2016-06       Impact factor: 1.276

6.  Global coagulation assays in hemophilia A: A comparison to conventional assays.

Authors:  Saman Aghighi; Anne Riddell; Christine A Lee; Simon A Brown; Edward Tuddenham; Pratima Chowdary
Journal:  Res Pract Thromb Haemost       Date:  2019-12-29

7.  Assessment of aPTT-based clot waveform analysis for the detection of haemostatic changes in different types of infections.

Authors:  Chuen Wen Tan; Wan Hui Wong; McVin Hua Heng Cheen; Yvonne Miao Hui Chu; Shan Shan Lim; Lawrence Cheng Kiat Ng; Dillon Guo Dong Yeo; Gayathry Morvil; Lai Heng Lee; Heng Joo Ng
Journal:  Sci Rep       Date:  2020-08-25       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.